Comparative Pharmacology
Head-to-head clinical analysis: OSMOPREP versus POLYETHYLENE GLYCOL 3350.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OSMOPREP versus POLYETHYLENE GLYCOL 3350.
OSMOPREP vs POLYETHYLENE GLYCOL 3350
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Osmotic laxative. Sodium phosphate draws water into the intestinal lumen via osmotic gradient, increasing intraluminal pressure and stimulating peristalsis.
Osmotic laxative. Polyethylene glycol 3350 is a non-absorbable polymer that retains water in the colon via hydrogen bonding, increasing stool water content and stimulating defecation.
3 tablets orally in the evening before colonoscopy, followed by 3 tablets the next morning, each dose with at least 1.5 L of clear liquids; maximum 6 tablets total.
17 g (1 capful or packet) dissolved in 4–8 oz (120–240 mL) water, administered orally once daily for constipation; for colonoscopy preparation, 240 g (4 L of solution) ingested at 240 mL every 10–15 minutes.
None Documented
None Documented
The terminal elimination half-life of the absorbed fraction is approximately 2.7 hours. This short half-life indicates rapid renal clearance of the small amount absorbed; however, the clinical effect (bowel cleansing) is independent of systemic elimination.
Terminal elimination half-life is 1-2 hours in patients with normal renal function; prolonged in renal impairment, but clinical impact minimal due to primarily fecal elimination.
Osmoprep (sodium phosphate monobasic monohydrate and sodium phosphate dibasic anhydrous) is not significantly absorbed systemically; the majority of the administered dose remains in the gastrointestinal tract and is eliminated in the feces. Less than 1% of the dose is absorbed and subsequently excreted unchanged in the urine via renal filtration.
Renal: approximately 20% excreted unchanged; Fecal: approximately 80% eliminated unchanged in feces.
Category C
Category C
Osmotic Laxative
Osmotic Laxative